Impact of cancer research bureaucracy on innovation, costs, and patient care

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 376-378

  Steensma, David P ^a   Kantarjian, Hagop M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ADVANCED CANCER; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; LEUKEMIA; LIFE SUSTAINING TREATMENT; LIFESTYLE MODIFICATION; MEDICAL SCHOOL; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NATIONAL HEALTH ORGANIZATION; NOTE; PATIENT CARE; PATIENT SAFETY; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROFIT; PRURITUS; QUALITY OF LIFE; REASSURANCE; RISK ASSESSMENT; SURVIVAL FACTOR; SWEATING; UNIVERSITY HOSPITAL; ARTICLE; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; LEGAL ASPECT; MASS COMMUNICATION; MEDICAL RESEARCH; ONCOLOGY; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; STANDARD; WORKFLOW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONTRACT SERVICES; DIFFUSION OF INNOVATION; ETHICS COMMITTEES, RESEARCH; GOVERNMENT REGULATION; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; MEDICAL ONCOLOGY; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; RESEARCH SUPPORT AS TOPIC; WORKFLOW;

EID: 84897572155     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.2548     Document Type: Note

References (26)

1. Rosanoff MA: Edison in his laboratory. Harper's Monthly 165:402-417, 1932
2. Dilts DM, Cheng SK, Crites JS, et al: Phase III clinical trial development: A process of chutes and ladders. Clin Cancer Res 16:5381-5389, 2010
3. Steensma DP: The ordinary miracle of cancer clinical trials. J Clin Oncol 27:1737-1739, 2009
4. Ginn S: Global clinical trials are burdened by excessive bureaucracy, conference hears. BMJ 343:d6322, 2011
5. Califf RM: Clinical trials bureaucracy: Unintended consequences of well-intentioned policy. Clin Trials 3:496-502, 2006
6. Mirowski P, Van Horn R: The contract research organization and the commercialization of scientific research. Soc Stud Sci 35:503-548, 2005 (Pubitemid 41186379)
7. Cutting Edge Information: Clinical operations: Benchmarking per-patient trial costs, staffing and adaptive design. http://www.cuttingedgeinfo.com/ research/clinical-development/trial-operations/
8. Atkinson TM, Li Y, Coffey CW, et al: Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159-1164, 2012
9. Hillman SL, Mandrekar SJ, Bot B, et al: Evaluation of the value of attribution in the interpretation of adverse event data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 28:3002-3007, 2010
10. Siddiqui M, Rajkumar SV: The high cost of cancer drugs and what we can do about it. Mayo Clin Proc 87:935-943, 2012
11. Hirsch BR, Schulman KA: The economics of new drugs. Am Soc Clin Oncol Ed Book 126-130, 2013
12. Ley TJ: E. Donnall Thomas lecture. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 8-11, 2012
13. Ley TJ, Anagnou NP, Noguchi CT, et al: DNA methylation and globin gene expression in patients treated with 5-azacytidine. Prog Clin Biol Res 134:457-474, 1983
14. Snooks H, Hutchings H, Seagrove A, et al: Bureaucracy stifles medical research in Britain: A tale of three trials. BMC Med Res Methodol 12:122, 2012
15. Dilts DM, Sandler AB: Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24:4545-4552, 2006 (Pubitemid 46630949)
16. Dilts DM, Sandler AB, Baker M, et al: Processes to activate phase III clinical trials in a cooperative oncology group: The case of Cancer and Leukemia Group B. J Clin Oncol 24:4553-4557, 2006 (Pubitemid 46630950)
17. Steensma DP: Processes to activate phase III clinical trials in a cooperative oncology group: The elephant is monstrous. J Clin Oncol 25:1148; reply 1148-1149, 2007
18. Dilts DM, Sandler A, Cheng S, et al: Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group. Clin Cancer Res 14:3427-3433, 2008
19. Dilts DM, Sandler AB, Cheng SK, et al: Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27:1761-1766, 2009
20. von Mises L: Bureaucracy. New Haven, Yale University Press, 1944
21. Mather M: Enlisted sailors forced out while Navy has more admirals than ships. http://wtkr.com/2013/05/02/enlisted-forced-out-while-navy-has-more- admirals-than-ships/
22. Parkinson CN: Parkinson's Law: The Pursuit of Progress. London, United Kingdom, John Murray, 1958
23. Ravina B, Deuel L, Siderowf A, et al: Local institutional review board (IRB) review of a multicenter trial: Local costs without local context. Ann Neurol 67:258-260, 2010
24. Desch K, Li J, Kim S, et al: Analysis of informed consent document utilization in a minimal-risk genetic study. Ann Intern Med 155:316-322, 2011
25. Daugherty C, Ratain MJ, Grochowski E, et al: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062-1072, 1995
26. Anonymous: Uninformed consent? Nat Med 13:999, 2007